This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
SURF 株式概要
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. 詳細
Surface Oncology, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.07 |
| 52週高値 | US$1.43 |
| 52週安値 | US$0.56 |
| ベータ | 1.75 |
| 11ヶ月の変化 | 11.47% |
| 3ヶ月変化 | 38.96% |
| 1年変化 | -21.90% |
| 33年間の変化 | -83.79% |
| 5年間の変化 | -89.91% |
| IPOからの変化 | -91.97% |
最新ニュース
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11株主還元
| SURF | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -0.9% | 4.0% | 2.0% |
| 1Y | -21.9% | 18.0% | 32.4% |
業界別リターン: SURF過去 1 年間で18 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: SURFは、過去 1 年間で32.4 % のリターンを上げたUS市場を下回りました。
価格変動
| SURF volatility | |
|---|---|
| SURF Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: SURFの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: SURFの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2014 | 35 | Rob Ross | www.surfaceoncology.com |
Surface Oncology, Inc. 基礎のまとめ
| SURF 基礎統計学 | |
|---|---|
| 時価総額 | US$65.08m |
| 収益（TTM） | -US$92.50m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-0.7x
PER（株価収益率SURF は割高か？
公正価値と評価分析を参照収益と収入
| SURF 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$67.00m |
| 売上総利益 | -US$67.00m |
| その他の費用 | US$25.50m |
| 収益 | -US$92.50m |
直近の収益報告
Jun 30, 2023
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.52 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
SURF の長期的なパフォーマンスは？
過去の実績と比較を見る